Xuesen Zhang

Dr. Xuesen Zhang


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2019 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
FLFujun Li
Fujun Li
LMLixia Miao
Lixia Miao
TXTeng Xue
Teng Xue
HQHao Qin
Hao Qin
SMSantanu Mondal
Santanu Mondal
XZXuesen Zhang
Xuesen Zhang
Background: Tamoxifen resistance presents a huge clinical challenge for breast cancer patients. An understanding of the mechanisms of tamoxifen resistance can guide development of efficient therapies to prevent drug resistance. Methods: We first tested whether peptidylarginine deiminase 2 (PAD2) may be involved in tamoxifen-resistance in breast cancer cells. The effect of depleting or inhibiting PAD2 in tamoxifen-resistant MCF-7 (MCF7/TamR) cells was evaluated both in vitro and in vivo. We then investigated the potential of Cl-amidine, a PAD inhibitor, to be used in combination with tamoxifen or docetaxel, and further explored the mechanism of the synergistic and effective drug regimen of PADs inhibitor and docetaxel on tamoxifen-resistant breast cancer cells. Results: We report that PAD2 is dramatically upregulated in tamoxifen-resistant breast cancer. Depletion of PAD2 in MCF7/TamR cells facilitated the sensitivity of MCF7/TamR cells to tamoxifen. Moreover, miRNA-125b-5p negatively regulated PAD2 expression in MCF7/TamR cells, therefore overexpression of miR-125b-5p also increased the cell sensitivity to tamoxifen. Furthermore, inhibiting PAD2 with Cl-amidine not only partially restored the sensitivity of MCF7/TamR cells to tamoxifen, but also more efficiently enhanced the efficacy of docetaxel on MCF7/TamR cells with lower doses of Cl-amidine and docetaxel both in vivo and in vivo. We then showed that combination treatment with Cl-amidine and docetaxel enhanced p53 nuclear accumulation, which synergistically induced cell cycle arrest and apoptosis. Meanwhile, p53 activation in the combination treatment also accelerated autophagy processes by synergistically decreasing the activation of Akt/mTOR signaling, thus enhancing the inhibition of proliferation. Conclusion: Our results suggest that PAD2 functions as an important new biomarker for tamoxifen-resistant breast cancers and that inhibiting PAD2 combined with docetaxel may offer a new approach to treatment of tamoxifen-resistant breast cancers.

1 September 2018 in Toxicology Letters
Verified
Journal Article
Closed access
XLXiaozhao Li
Xiaozhao Li
CBChunyu Bao
Chunyu Bao
ZMZhinan Ma
Zhinan Ma
BXBoqun Xu
Boqun Xu
XYXiaoyan Ying
Xiaoyan Ying
XZXuesen Zhang
Xuesen Zhang

1 November 2017 in Cancer Letters
Verified
Journal Article
Closed access
HQHao Qin
Hao Qin
XLXiaoqiu Liu
Xiaoqiu Liu
FLFujun Li
Fujun Li
LMLixia Miao
Lixia Miao
TLTingting Li
Tingting Li
XZXuesen Zhang
Xuesen Zhang

29 January 2021 in Advanced Science
Verified
Journal Article
Open access
PDF file
TXTeng Xue
Teng Xue
XLXiaoqiu Liu
Xiaoqiu Liu
MZMei Zhang
Mei Zhang
QEQiukai E
Qiukai E
SLShuting Liu
Shuting Liu
XZXuesen Zhang
Xuesen Zhang
Peptidylarginine deiminase II (PADI2) converts positively charged arginine residues to neutrally charged citrulline, and this activity has been associated with the onset and progression of multiple cancers. However, a role for PADI2 in endometrial cancer (EC) has not been previously explored. This study demonstrates that PADI2 is positively associated with EC proregression. Mechanistically, PADI2 interacting and catalyzing MEK1 citrullination at arginine 113/189 facilitates MEK1 on extracellular signal‐regulated protein kinases 1/2 (ERK1/2) phosphorylation, which activates insulin‐like growth factor‐II binding protein 1 (IGF2BP1) expression. Furthermore, RNA immunoprecipitation (RIP) and RNA stability analyses reveal that IGF2BP1 binds to the m6A sites in SOX2‐3′UTR to prevent SOX2 mRNA degradation. Dysregulation of IGF2BP1 by PADI2/MEK1/ERK signaling results in abnormal accumulation of oncogenic SOX2 expression, therefore supporting the malignant state of EC. Finally, PADI2 gene silencing, inhibiting MEK1 citrullination by PADI2 inhibitor, or mutation of MEK1 R113/189 equally inhibits EC progression. These data demonstrate that PADI2‐catalyzed MEK1 R113/189 citrullination is a critical diver for EC malignancies and suggest that targeting PADI2/MEK1 can be a potential therapeutic approach in patients with EC.

8 December 2016 in Scientific Reports
Verified
Journal Article
Open access
XZXiaoqian Zhang
Xiaoqian Zhang
XLXiaoqiu Liu
Xiaoqiu Liu
MZMei Zhang
Mei Zhang
TLTingting Li
Tingting Li
AMAaron Muth
Aaron Muth
XZXuesen Zhang
Xuesen Zhang
Peptidylarginine deiminase (PADI) enzymes are increasingly being associated with the regulation of chromatin structure and gene activity via histone citrullination. As one of the PADI family members, PADI1 has been mainly reported to be expressed in the epidermis and uterus, where the protein in keratinocytes is thought to promote differentiation by citrullinating filament proteins. However, the roles of PADI1 in preimplantation development have not been addressed. Using a PADI1-specific inhibitor and Padi1-morpholino knockdown, we found that citrullination of histone tails at H4R3 and H3R2/8/17 were markedly reduced in the 2- and 4-cell embryos. Consistent with this observation, early embryo development was also arrested at the 4-cell stage upon depletion of PADI1 or inhibition of PADI1 enzyme activity. Additionally, by employing 5-ethynyl uridine (EU) incorporation analysis, ablation of PADI1 function led to a dramatic decrease in overall transcriptional activity, correlating well with the reduced levels of phosphorylation of RNA Pol II at Ser2 observed at 2- or 4-cell stage of embryos under Padi1 knockdown or inhibiting PADI1. Thus, our data reveal a novel function of PADI1 during early embryo development transitions by catalyzing histone tail citrullination, which facilitates early embryo genome transactivation.

1 June 2020 in Metabolism
Verified
Journal Article
Closed access
XZXiaoqian Zhang
Xiaoqian Zhang
HXHua Xiao
Hua Xiao
XZXueying Zhang
Xueying Zhang
QEQiukai E.
Qiukai E.
XGXuefeng Gong
Xuefeng Gong
XZXuesen Zhang
Xuesen Zhang